HomeCompareEMMLF vs QYLD

EMMLF vs QYLD: Dividend Comparison 2026

EMMLF yields 14598.54% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMMLF wins by $2315127447129181184.00M in total portfolio value
10 years
EMMLF
EMMLF
● Live price
14598.54%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2315127447129181184.00M
Annual income
$2,284,345,916,069,374,600,000,000.00
Full EMMLF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — EMMLF vs QYLD

📍 EMMLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMMLFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMMLF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMMLF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMMLF
Annual income on $10K today (after 15% tax)
$1,240,875.91/yr
After 10yr DRIP, annual income (after tax)
$1,941,694,028,658,968,500,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, EMMLF beats the other by $1,941,694,028,658,968,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMMLF + QYLD for your $10,000?

EMMLF: 50%QYLD: 50%
100% QYLD50/50100% EMMLF
Portfolio after 10yr
$1157563723564590592.00M
Annual income
$1,142,172,958,034,687,300,000,000.00/yr
Blended yield
98.67%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMMLF buys
0
QYLD buys
0
No recent congressional trades found for EMMLF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMMLFQYLD
Forward yield14598.54%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2315127447129181184.00M$25.4K
Annual income after 10y$2,284,345,916,069,374,600,000,000.00$5,659.31
Total dividends collected$2313090038871241728.00M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: EMMLF vs QYLD ($10,000, DRIP)

YearEMMLF PortfolioEMMLF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$1,470,554$1,459,854.01$10,352$1,192.36+$1.46MEMMLF
2$202,208,463$200,634,970.27$10,830$1,347.57+$202.20MEMMLF
3$25,999,823,322$25,783,460,266.67$11,460$1,539.07+$25999.81MEMMLF
4$3,126,155,661,671$3,098,335,850,716.16$12,275$1,777.84+$3126155.65MEMMLF
5$351,509,831,288,492$348,164,844,730,504.60$13,323$2,078.95+$351509831.28MEMMLF
6$36,963,217,951,789,784$36,587,102,432,311,096.00$14,667$2,463.34+$36963217951.78MEMMLF
7$3,635,193,394,947,107,000$3,595,642,751,738,691,600.00$16,396$2,960.57+$3635193394947.09MEMMLF
8$334,373,707,794,473,750,000$330,484,050,861,880,400,000.00$18,631$3,612.97+$334373707794473.75MEMMLF
9$28,767,786,037,201,900,000,000$28,410,006,169,861,807,000,000.00$21,548$4,482.15+$28767786037201900.00MEMMLF
10$2,315,127,447,129,181,000,000,000$2,284,345,916,069,374,600,000,000.00$25,398$5,659.31+$2315127447129181184.00MEMMLF

EMMLF vs QYLD: Complete Analysis 2026

EMMLFStock

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Full EMMLF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this EMMLF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMMLF vs SCHDEMMLF vs JEPIEMMLF vs OEMMLF vs KOEMMLF vs MAINEMMLF vs XYLDEMMLF vs JEPQEMMLF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.